Advertisement

Labormedizin pp 133-174 | Cite as

Medikamentenspiegel-Bestimmungen (Therapeutisches Drug Monitoring — TDM)

  • G. Halwachs-Baumann
  • A. Meinitzer
  • G. A. Khoschsorur
Chapter
  • 5.7k Downloads

Auszug

Das therapeutische Drug Monitoring (TDM), d.h. die Bestimmung von Medikamentenkonzentrationen im Blut, ist vor allem bei der Therapie mit Substanzen, die einen engen therapeutischen Wirkungsbereich haben, wichtig. Nur so kann überprüft werden, ob eine Unter- oder eine (eventuell toxische oder organschädigende) Überdosierung vorhanden ist. Die Effizienz der Therapie wird gesteigert, unnötige Kosten und Nebenwirkungen können durch ein richtig durchgeführtes TDM vermieden werden. Eine Überprüfung der Konzentration im Blut ist aber nicht bei jedem Medikament notwendig. Die Indikationen für ein TDM sind in Tabelle 5.1 aufgelistet.

Tabelle 5.1.

Indikationen für ein therapeutisches Drug Monitoring (TDM)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Allgemein

  1. Ellenhorn M J (1997) Medical toxicology. Williams & Wilkins, PhiladelphiaGoogle Scholar
  2. Licinio J, Wong M L (2002) Pharmacogenomics. Wiley-VCH Verlag GmbH, WeinheimCrossRefGoogle Scholar
  3. Schonwald S (2001) Medical toxicology. A synopsis and study guide. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  4. Schütz H (1999) Screening von Drogen und Arzneimitteln mit Immunoassays. Wissenschaftliche Verlagsabteilung Abbott GmbH, WiesbadenGoogle Scholar
  5. Warner A, Annesley T (1998) Guidelines for therapeutic drug monitoring services. The National Academy of Clinical BiochemistryGoogle Scholar

Speziell

  1. 3.
    Newman L S, Feinberg M W, LeWine H E (2004) A bitter tale. N Engl J Med 351(6): 594–599PubMedCrossRefGoogle Scholar
  2. 4.
    Quazzaz H M A M, Cao T Z, Bolanowski D D, Clark B J, Valdes R (2004) De novo biosynthesis and radiolabeling of mammalian digitalis-like factors. Clin Chem 50(3): 612–620CrossRefGoogle Scholar
  3. 5.
    Dasbupta A (2002) Endogenous and exogenous digoxin-like immunoreactive substances. Am J Clin Pathol 118: 132–140CrossRefGoogle Scholar
  4. 6.
    Berendes E, Cullen P, Van Aken H, Zidek W, Erren M, Hubschen M, Weber T, Wirtz S, Tepel M, Walter M (2003) Endogenous glycosides in critically ill patients. Crit Care Med 31(5): 1331–1337PubMedCrossRefGoogle Scholar
  5. 7.
    Steimer W, Müller C, Eber B (2002) Digoxin assays: Frequent, substantial, and potentially danerous interference by spironolactone, canrenone, and other steroids. Clin Chem 48(3): 507–516PubMedGoogle Scholar
  6. 8.
    Steimer W, Müller C, Eber B, Emmanuilidis K (1999) Intoxication due to negative canrenone interference in digoxin drug monitoring. Lancet 354: 1176–1177PubMedCrossRefGoogle Scholar
  7. 9.
    Pesce A J, Rashkin M, Kotagal U (1998) Standards of laboratory practice: theophylline and caffeine monitoring. Clin Chem 44(5): 1124–1128PubMedGoogle Scholar
  8. 10.
    Midtvedt K (2004) Therapeutic drug monitoring of cyclosporine. Transplant Proc 36[Suppl 2S]: 430S–433SPubMedCrossRefGoogle Scholar
  9. 11.
    Mahalati K, Belitsky P, Sketris I, West K, Panek R (1999) Neoral monitoring by simplified sparse sampling area under the concentration-time curve: ist relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68(1): 55–62PubMedCrossRefGoogle Scholar
  10. 12.
    Johnston A, Chusney G, Schütz E, Oellerich M, Lee T D, Holt D W (2003) Monitoring cyclosporin in blood: between-assay differences at trough and 2 hours post-dose (C2). Ther Drug Monit 25: 167–173PubMedCrossRefGoogle Scholar
  11. 13.
    Undre N A, Schäfer A, and the European Tacrolimus Multicentre Renal Study Group (1998) Factors affecting the parmacokinetics of tacrolimus in the first year after renal transplantation. Transplant Proc 30: 1261–1263PubMedCrossRefGoogle Scholar
  12. 14.
    Weber L T, Shipkova M, Lamersdorf T, Niedmann P D, Wiesel M, Mandelbaum A, Zimmerhackl L B, Schutz E, Mehls O, Oellerich M, Armstrong V W, Tonshoff B (1998) Pharmacokinetics of mycophenolic acid (MPA) and determinants of PMA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 9(8): 1511–1520PubMedGoogle Scholar
  13. 15.
    Shipkova M, Schütz E, Armstrong V W, Niedmann P D, Oellerich M, Wieland E (2000) Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and EMIT. Clin Chem 46(3): 365–372PubMedGoogle Scholar
  14. 16.
    Bleyzac N, Allard-Latour B, Laffont A, Mouret J, Jelliffe R, Maire P (2000) Diurnal changes in the parmacokinetic behavior of amikacin. Ther Drug Monit 22(3): 307–312PubMedCrossRefGoogle Scholar
  15. 17.
    Prins J M, Weverling G J, van Ketel R J, Speelman P (1997) Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther 62(1): 106–111PubMedCrossRefGoogle Scholar
  16. 18.
    Black F O, Pesznecker S, Stallings V (2004) Permanent gentamicin vestibulotoxicity. Otol Neurotol 25: 559–569PubMedCrossRefGoogle Scholar
  17. 19.
    McIntyre J, Choonara I (2004) Drug toxicity in the neonate. Biol Neonate 86: 218–221PubMedCrossRefGoogle Scholar
  18. 20.
    Iwamoto T, Kagawa Y, Kojima M (2003) Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 26(6): 876–879PubMedCrossRefGoogle Scholar
  19. 21.
    Iwamoto T, Kagawa Y, Kojima M (2005) Factors influencing the overestimation of plasma vancomycin concentrations measured by the Abbott TDx technique. Ther Drug Monit 27(1): 58–62PubMedCrossRefGoogle Scholar
  20. 22.
    Jannuzzi G, Cian P, Fattore C, Gatti G, Bartoli A, Monaco F, Perucca E A (2000) Multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epileplsy. The Italian TDM Study Grup in Epilepsy. Epilepsia 41(2): 222–230PubMedCrossRefGoogle Scholar
  21. 23.
    Tomson T, Johannessen S I (2000) Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 55(10): 697–705PubMedCrossRefGoogle Scholar
  22. 24.
    Mattson R H (1995) Antiepileptic drug monitoring: a reappraisal. Epilepsia 36[Suppl 5]:S22–S29PubMedCrossRefGoogle Scholar
  23. 25.
    Schoenenberger R A, Tanasijevic M J, Jha A, Bates D W (1995) Appropriateness of antiepileptic drug level monitoring. JAMA 274(20): 1622–1626PubMedCrossRefGoogle Scholar
  24. 26.
    Affolter N, Krähenbühl S, Schlienger R G (2003) Appropriateness of serum level determinations of antiepileptic drugs. Swiss Med Wkly 133: 591–597PubMedGoogle Scholar
  25. 27.
    Warner A, Privitera M, Bates D (1998) Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem 44(5): 1085–1095PubMedGoogle Scholar
  26. 28.
    Martz W, Schutz H W (1991) Synthetic sweetener cyclamate as a potential source of false-positive amphetamine results in the TDx system. Clin Chem 37(11): 2016–2017PubMedGoogle Scholar
  27. 29.
    Fraser A D, Worth D (2002) Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: A cannabinoid-to-creatinine ratio study. Ther Drug Monit 24: 746–750PubMedCrossRefGoogle Scholar
  28. 30.
    Cassella G, Wu A H, Shaw B R, Hill D W (1997) The analysis of thebaine in urine fort he detection of poppy seed consumption. J Anal Toxicol 21(5): 376–383PubMedGoogle Scholar
  29. 31.
    Ceder G, Jones A W (2001) Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine. Clin Chem 47(11): 1980–1984PubMedGoogle Scholar
  30. 32.
    Needleman S B, Porvaznik M, Ander D (1992) Creatinin analysis in single collection urine specimens. J Forensic Sci 37(4): 1125–1133PubMedGoogle Scholar
  31. 33.
    Lafolie P, Beck O, Blennow G, Boreus L, Borg S, Elmin C E, Karlsson L, Odelius G, Hjemdahl P (1991) Importance of creatinine analysies of urine when screening for abused drugs. Clin Chem 37(11): 1927–1931PubMedGoogle Scholar
  32. 34.
    Wagener R E, Linder M W, Valdes R Jr (1994) Decreased signal in Emit assays of drugs of abuse in urine after ingestion of aspirin: potential for false-negative results. Clin Chem 40(4): 608–612PubMedGoogle Scholar
  33. 35.
    Karch S B, Stephens B G, Nazareno G V (2001 ) GHB. Club drug or confusing artifact? Am J Forensic Med Pathol 22(3): 266–269PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2011

Authors and Affiliations

  • G. Halwachs-Baumann
    • 1
  • A. Meinitzer
    • 2
  • G. A. Khoschsorur
    • 2
  1. 1.Krankenhaus Steyr, Institut für Medizinische und Chemische LabordiagnostikSteyr
  2. 2.Medizinische Universität GrazKlinisches Institut für Medizinische und Chemische LabordiagnostikGraz

Personalised recommendations